We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
Source
